NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Asthma

Countries: China

This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician.

Eligibility overview

Sex: ALL

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Chinese, Female or Male
2. Age: no limitation
3. Physician-confirmed asthma diagnosis with documented evidence of diagnosis or evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests).
4. Participants or their legal guardians must be able to provide informed consent.
5. Prescription of asthma biologics at enrolment.

   Exclusion Criteria:
6. Participation in an interventional study within the last 3 months.
7. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study with the usage of biologics, or may influence the results of the study, or the patient's ability to participate in the study

Locations (30)

Hohhot, China, China
Beijing, China
Changsha, China
Chengdu, China
Foshan, China
Fuzhou, China
Guangzhou, China
Hangzhou, China
Hefei, China
Jinan, China
Kunming, China
Nanchang, China
Nanjing, China
Ningbo, China
Qingdao, China
Quanzhou, China
Shanghai, China
Shenyang, China
Shenzhen, China
Shijiazhuang, China
Suining, China
Taiyuan, China
Tianjin, China
Ürümqi, China
Wenzhou, China
Wuhan, China
Wuxi, China
Xi'an, China
Zhengzhou, China
Zhuhai, China